logo

For the Inventor, By the Inventor

Brampton, Canada

Blaise N'Zemba

This inventor holds 10 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignees: Apotex Technologies Inc., Other. Active years: 2012-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Blaise N'Zemba. Retrieved from https://idiyas.com/inventor/blaise-n-zemba

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 

% Patents Active = 10.0

 

Average Co-Inventor Count = 6.4

ph-index = 1


Company Filing History:

goldMedal9 out of 13 
 
Apotex Technologies Inc.
 patents
silverMedal1 out of 834,513 
Other
 patents

Years Active: 2012-2017

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents
1. 9550733 - Fluorinated derivatives of 3-hydroxypyridin-4-ones (2017-01-24),
2. 9073865 - Fluorinated derivates of 3-hydroxypyridin-4-ones (2015-07-07),
3. 8735602 - Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture (2014-05-27),
4. 8664262 - Crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan (2014-03-04),
5. 8507449 - Crystalline D-isoglutamyl-D-tryptophan and the mono ammonium salt of D-isoglutamyl-D-tryptophan (2013-08-13),
6. 8481588 - Crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan (2013-07-09),
7. 8476235 - Crystalline D-isoglutamyl-D-tryptophan and the mono ammonium salt of D-isoglutamyl-D-tryptophan (2013-07-02),
8. 8207217 - Crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan (2012-06-26),
9. 8138221 - Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture (2012-03-20),
10. 8119606 - Crystalline D-isoglutamyl-D-tryptophan and the mono ammonium salt of D-isoglutamyl-D-tryptophan (2012-02-21),

Title: The Innovations of Blaise N'Zemba: Pioneering Medical Chemistry

Introduction

Blaise N'Zemba, an accomplished inventor based in Brampton, Canada, is renowned for his significant contributions to the field of medical chemistry. With an impressive portfolio of 10 patents, N'Zemba has focused his research on innovative compounds aimed at treating conditions associated with toxic concentrations of iron in the body.

Latest Patents

Among his latest patents, N'Zemba has developed fluorinated derivatives of 3-hydroxypyridin-4-ones. These groundbreaking compounds, represented by Formula I, are designed to address medical conditions related to iron toxicity. The compounds are particularly valuable in the formulation of medicaments for treating conditions such as cancer, pulmonary disease, progressive kidney disease, and Friedreich's ataxia.

Career Highlights

N'Zemba’s distinguished career includes significant tenure at Apotex Technologies Inc., where he has applied his expertise in medicinal chemistry. His innovative approach and commitment to enhancing therapeutic options have established him as a leader in his field.

Collaborations

Throughout his career, N'Zemba has collaborated with notable professionals, including Tim Fat Tam and Yingsheng Wang. Their collective efforts have led to the advancement of various research initiatives aimed at improving patient care and treatment efficacy.

Conclusion

Blaise N'Zemba continues to make remarkable strides in the realm of medical innovations. His contributions not only reflect his creativity and scientific acumen but also highlight the ongoing quest for effective treatments for serious health conditions. As he continues to innovate, the medical community eagerly anticipates the potential impacts of his future inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…